- Home
- CRBP vs CAPN Comparison
CRBP vs CAPN Comparison
Compare CRBP & CAPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- CAPN
- Stock Information
- Founded
- CRBP 2009
- CAPN 2024
- Country
- CRBP United States
- CAPN United States
- Employees
- CRBP N/A
- CAPN N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- CAPN
- Sector
- CRBP Health Care
- CAPN
- Exchange
- CRBP Nasdaq
- CAPN NYSE
- Market Cap
- CRBP 73.4M
- CAPN 74.7M
- IPO Year
- CRBP N/A
- CAPN 2024
- Fundamental
- Price
- CRBP $6.03
- CAPN N/A
- Analyst Decision
- CRBP Strong Buy
- CAPN
- Analyst Count
- CRBP 10
- CAPN 0
- Target Price
- CRBP $60.89
- CAPN N/A
- AVG Volume (30 Days)
- CRBP 207.2K
- CAPN 11.3K
- Earning Date
- CRBP 05-06-2025
- CAPN 01-01-0001
- Dividend Yield
- CRBP N/A
- CAPN N/A
- EPS Growth
- CRBP N/A
- CAPN N/A
- EPS
- CRBP N/A
- CAPN N/A
- Revenue
- CRBP N/A
- CAPN N/A
- Revenue This Year
- CRBP N/A
- CAPN N/A
- Revenue Next Year
- CRBP $150.00
- CAPN N/A
- P/E Ratio
- CRBP N/A
- CAPN N/A
- Revenue Growth
- CRBP N/A
- CAPN N/A
- 52 Week Low
- CRBP $4.64
- CAPN $9.95
- 52 Week High
- CRBP $61.90
- CAPN $10.47
- Technical
- Relative Strength Index (RSI)
- CRBP 49.07
- CAPN N/A
- Support Level
- CRBP $5.68
- CAPN N/A
- Resistance Level
- CRBP $6.29
- CAPN N/A
- Average True Range (ATR)
- CRBP 0.46
- CAPN 0.00
- MACD
- CRBP 0.19
- CAPN 0.00
- Stochastic Oscillator
- CRBP 84.24
- CAPN 0.00
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About CAPN CAYSON ACQUISITION CORP
Cayson Acquisition Corp is a blank check company.